Skip to main content
. 2024 Jan 22;15:1321058. doi: 10.3389/fneur.2024.1321058

Figure 2.

Figure 2

The patient’s clinical course after admission as assessed by the myasthenia gravis composite (MGC) scale. Note that the serial assessments of the patient’s serum anti-AChR antibody titers paralleled the clinical improvements assessed by the MGC scale after efgartigimod administration.